Outcomes based on albumin-bilirubin (ALBI) grade in the phase III CELESTIAL trial of cabozantinib versus placebo in patients with advanced hepatocellular carcinoma (HCC)

被引：0
|
作者：
Chan, S. L. [1 ]
Miksad, R. [2 ]
Cicin, I. [3 ]
Chen, Y. [4 ]
Klumpen, H. J. [5 ]
Kim, S. [6 ]
Lin, Z. Z. [7 ]
Youkstetter, J. [8 ]
Sen, S. [8 ]
Cheng, A-L. [9 ]
El-Khoueiry, A. B. [10 ]
Meyer, T. [11 ]
Kelley, R. K. [12 ]
Abou-Alfa, G. K. [13 ]
机构：
[1] Chinese Univ Hong Kong, Dept Clin Oncol, State Key Lab Oncol South China, Hong Kong, Peoples R China
[2] Beth Israel Deaconess Med Ctr, Res Oncol, New York, NY USA
[3] Trakya Univ, Dept Med Oncol, Edirne, Turkey
[4] Chinese Univ Hong Kong, Dept Clin Oncol, Hong Kong, Peoples R China
[5] AMC, Med Oncol, Amsterdam, Netherlands
[6] Ctr Hosp Reg Univ Besancon, Med Oncol, Besancon, France
[7] Natl Taiwan Univ Hosp, Dept Oncol, Taipei, Taiwan
[8] Exelixis Inc, Dept Oncol, Alameda, CA USA
[9] Natl Taiwan Univ Hosp, Canc Ctr, Taipei, Taiwan
[10] Univ Southern Calif, Norris Comprehens Canc Ctr, Med Oncol, Los Angeles, CA USA
[11] UCL, Dept Oncol, London, England
[12] USCSF Hellen Diller Family Comprehens Canc Ctr, Med, San Francisco, CA USA
[13] Mem Sloan Kettering Canc Ctr, Dept Oncol, 1275 York Ave, New York, NY 10021 USA
来源：
ANNALS OF ONCOLOGY | 2019年 / 30卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
127P
引用
收藏
页数：2
相关论文
共 50 条
  • [1] Outcomes based on Albumin-Bilirubin (ALBI) grade in the phase 3 CELESTIAL trial of cabozantinib versus placebo in patients with advanced hepatocellulat carcinoma (HCC)
    Miksad, R.
    Cicin, I.
    Chen, Y.
    Klumpen, H.
    Kim, S.
    Lin, Z.
    Youkstetter, J.
    Sen, S.
    Cheng, A.
    Meyer, T.
    Kelley, R.
    Abou-Alfa, G.
    ANNALS OF ONCOLOGY, 2019, 30 : 134 - 134
  • [2] Outcomes based on albumin-bilirubin grade in the phase 3 RESORCE trial of regorafenib versus placebo in patients with advanced hepatocellular carcinoma
    Vogel, A.
    Merle, P.
    Granito, A.
    Ikeda, M.
    LeBerre, M. -A
    Ozgurdal, K.
    Bruix, J.
    ONCOLOGY RESEARCH AND TREATMENT, 2021, 44 : 223 - 223
  • [3] Outcomes based on plasma biomarkers for the Phase III CELESTIAL trial of cabozantinib versus placebo in advanced hepatocellular carcinoma
    Zekry, A.
    Rimassa, L.
    Kelley, R.
    Meyer, T.
    Ryoo, B.
    Merle, P.
    Park, J.
    Blanc, J.
    Lim, H.
    Tran, A.
    Borgman-Hagey, A.
    Clary, D.
    Wang, E.
    Cheng, A.
    El-Khoueiry, A.
    Abou-Alfa, G.
    JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2019, 34 : 41 - 42
  • [4] Efficacy and safety of cabozantinib for patients with advanced hepatocellular carcinoma based on albumin-bilirubin grade
    Robin Kate Kelley
    Rebecca Miksad
    Irfan Cicin
    YenHsun Chen
    Heinz-Josef Klümpen
    Stefano Kim
    Zhong-Zhe Lin
    Jillian Youkstetter
    Saswati Hazra
    Suvajit Sen
    Ann-Lii Cheng
    Anthony B. El-Khoueiry
    Tim Meyer
    Ghassan K. Abou-Alfa
    British Journal of Cancer, 2022, 126 : 569 - 575
  • [5] Efficacy and safety of cabozantinib for patients with advanced hepatocellular carcinoma based on albumin-bilirubin grade
    Kelley, Robin Kate
    Miksad, Rebecca
    Cicin, Irfan
    Chen, YenHsun
    Klumpen, Heinz-Josef
    Kim, Stefano
    Lin, Zhong-Zhe
    Youkstetter, Jillian
    Hazra, Saswati
    Sen, Suvajit
    Cheng, Ann-Lii
    El-Khoueiry, Anthony B.
    Meyer, Tim
    Abou-Alfa, Ghassan K.
    BRITISH JOURNAL OF CANCER, 2022, 126 (04) : 569 - 575
  • [6] Outcomes based on age in the phase 3 CELESTIAL trial of cabozantinib (C) versus placebo (P) in patients (pts) with advanced hepatocellular carcinoma (HCC).
    Rimassa, Lorenza
    Cicin, Irfan
    Blanc, Jean-Frederic
    Klumpen, Heinz Josef
    Zagonel, Vittorina
    Tran, Albert
    Kim, Stefano Chong Hun
    Lin, Zhong-Zhe
    Tam, Vincent C.
    Hazra, Saswati
    Mangeshkar, Milan
    El-Khoueiry, Anthony
    Cheng, Ann-Lii
    Meyer, Tim
    Kelley, Robin Kate
    Abou-Alfa, Ghassan K.
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [7] Outcomes based on age in the phase 3 CELESTIAL trial of cabozantinib (C) versus placebo (P) in patients (pts) with advanced hepatocellular carcinoma (HCC)
    Venerito, M.
    Rimassa, L.
    Cicin, I
    Blanc, J-F
    Kluempen, H-J
    Zagonel, V
    Tran, A.
    Kim, S.
    Lin, Z-Z
    Tam, V. C.
    Hazra, S.
    Mangeshkar, M.
    El-Khoueiry, A. B.
    Cheng, A-L
    Meyer, T.
    Kelley, R. K.
    Abou-Alfa, G. K.
    ONCOLOGY RESEARCH AND TREATMENT, 2018, 41 : 283 - 283
  • [8] Assessment of disease burden in the phase III CELESTIAL trial of cabozantinib (C) versus placebo (P) in advanced hepatocellular carcinoma (HCC)
    Blanc, J. F.
    Meyer, T.
    Cheng, A-L.
    El-Khoueiry, A. B.
    Cicin, I.
    Chen, Y.
    Bolondi, L.
    Dadduzio, V.
    Baron, A.
    Lin, Z-Z.
    Adriani, J.
    Kelly, R. K.
    Abou-Alfa, G. K.
    ANNALS OF ONCOLOGY, 2018, 29 : 237 - 237
  • [9] Outcomes by prior transarterial chemoembolization (TACE) in the phase III CELESTIAL trial of cabozantinib (C) versus placebo (P) in patients (pts) with advanced hepatocellular carcinoma (HCC)
    Yau, T.
    Cheng, A-L.
    Meyer, T.
    Ryoo, B-Y.
    Park, J-W.
    Klumpen, H-J.
    Lim, H. Y.
    Kim, S.
    Knox, J.
    Patel, M.
    El-Khoueiry, A. B.
    Kelley, R. K.
    Abou-Alfa, G. K.
    ANNALS OF ONCOLOGY, 2018, 29
  • [10] Outcomes Based on Plasma Biomarkers for the Phase 3 CELESTIAL Trial of Cabozantinib versus Placebo in Advanced Hepatocellular Carcinoma
    Rimassa, Lorenza
    Kelley, Robin Kate
    Meyer, Tim
    Ryoo, Baek-Yeol
    Merle, Philippe
    Park, Joong-Won
    Blanc, Jean-Frederic
    Lim, Ho Yeong
    Tran, Albert
    Chan, Yi-Wah
    McAdam, Paul
    Wang, Evelyn
    Cheng, Ann-Lii
    El-Khoueiry, Anthony B.
    Abou-Alfa, Ghassan K.
    LIVER CANCER, 2021, : 38 - 47
12345